GB202105186D0 - Pyrrolobenzodiazepine conjugates - Google Patents
Pyrrolobenzodiazepine conjugatesInfo
- Publication number
- GB202105186D0 GB202105186D0 GBGB2105186.7A GB202105186A GB202105186D0 GB 202105186 D0 GB202105186 D0 GB 202105186D0 GB 202105186 A GB202105186 A GB 202105186A GB 202105186 D0 GB202105186 D0 GB 202105186D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pyrrolobenzodiazepine conjugates
- pyrrolobenzodiazepine
- conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2105186.7A GB202105186D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
| PCT/EP2022/059733 WO2022218973A2 (en) | 2021-04-12 | 2022-04-12 | Pyrrolobenzodiazepine conjugates |
| TW111113931A TW202308697A (en) | 2021-04-12 | 2022-04-12 | Pyrrolobenzodiazepine conjugates |
| ARP220100927A AR125338A1 (en) | 2021-04-12 | 2022-04-12 | PYRROLOBENZODIAZEPINE CONJUGATES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2105186.7A GB202105186D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202105186D0 true GB202105186D0 (en) | 2021-05-26 |
Family
ID=75949544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2105186.7A Ceased GB202105186D0 (en) | 2021-04-12 | 2021-04-12 | Pyrrolobenzodiazepine conjugates |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR125338A1 (en) |
| GB (1) | GB202105186D0 (en) |
| TW (1) | TW202308697A (en) |
| WO (1) | WO2022218973A2 (en) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58180487A (en) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | Antibiotic dc-81 and its preparation |
| EP1720881B9 (en) | 2004-03-01 | 2013-04-17 | Spirogen Sàrl | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins |
| EP1879901B1 (en) | 2005-04-21 | 2009-12-23 | Spirogen Limited | Pyrrolobenzodiazepines |
| EP1813614B1 (en) | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
| PT2099823E (en) | 2006-12-01 | 2014-12-22 | Seattle Genetics Inc | Variant target binding agents and uses thereof |
| MA34277B1 (en) | 2010-04-15 | 2013-06-01 | Spirogen Developments Sarl | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF |
| JP6014596B2 (en) | 2010-11-09 | 2016-10-25 | メディミューン,エルエルシー | Antibody scaffold for homogeneous conjugation |
| KR101412875B1 (en) | 2012-10-04 | 2014-07-02 | 삼성전기주식회사 | Gate driving circuit and inverter having the same |
| JP5993093B2 (en) | 2012-10-12 | 2016-09-14 | メドイミューン・リミテッドMedImmune Limited | Pyrrolobenzodiazepines and their complexes |
| AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| ES2719584T3 (en) | 2014-04-11 | 2019-07-11 | Medimmune Llc | Conjugated compounds comprising genetically engineered antibodies modified with cysteine |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| KR20190083654A (en) | 2016-11-10 | 2019-07-12 | 메디뮨 엘엘씨 | Binding molecules specific for ASCT2 and uses thereof |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3801630A1 (en) | 2018-05-25 | 2021-04-14 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| AU2018430758B2 (en) * | 2018-07-05 | 2022-01-27 | Hangzhou Dac Biotech Co., Ltd | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivative and its conjugates |
| AU2018445278B2 (en) * | 2018-10-12 | 2022-07-28 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers containing 2,3-diaminosuccinyl group |
| GB2581394A (en) * | 2019-02-18 | 2020-08-19 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
-
2021
- 2021-04-12 GB GBGB2105186.7A patent/GB202105186D0/en not_active Ceased
-
2022
- 2022-04-12 WO PCT/EP2022/059733 patent/WO2022218973A2/en not_active Ceased
- 2022-04-12 AR ARP220100927A patent/AR125338A1/en unknown
- 2022-04-12 TW TW111113931A patent/TW202308697A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022218973A3 (en) | 2022-12-22 |
| WO2022218973A2 (en) | 2022-10-20 |
| AR125338A1 (en) | 2023-07-05 |
| TW202308697A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315508A (en) | Camptothecin conjugates | |
| IL287391A (en) | Amatoxin antibody-drug conjugates and uses thereof | |
| IL272625B1 (en) | Pyrrolobenzodiazepine conjugates | |
| IL269945B (en) | Pyrrolobenzodiazepine conjugates | |
| IL299362A (en) | Antibody-drug conjugates comprising anti-b7-h3 antibodies | |
| IL308811A (en) | Neodegrader conjugates | |
| IL291312A (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
| IL318188A (en) | Antibody-drug conjugates | |
| GB2594753B (en) | Antibody-drug conjugates | |
| GB201820864D0 (en) | Antibody-drug conjugates | |
| GB201902182D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| GB202105187D0 (en) | Pyrrolobenzodiazepine conjugates | |
| GB202105186D0 (en) | Pyrrolobenzodiazepine conjugates | |
| IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201908126D0 (en) | Pyrrolobenzodiazepine conjugates | |
| GB201905117D0 (en) | Pyrrolobenzodiazepine conjugates | |
| GB201906997D0 (en) | Conjugates | |
| IL319822A (en) | Neodegrader conjugates | |
| GB202210058D0 (en) | Conjugates | |
| GB202000121D0 (en) | Compounds and conjugates | |
| GB201817088D0 (en) | Pyrrolobenzodiazepine conjugates | |
| GB201817110D0 (en) | Pyrrolobenzodiazepine conjugates | |
| IL314507A (en) | Theragnostic folate conjugates | |
| IL324828A (en) | Ligand-polar drug conjugates | |
| HK40086516A (en) | Antibody-drug conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |